Acorda Therapeutics, Inc.
|Company Name||Acorda Therapeutics, Inc.|
On November 15, 2017, Acorda announced that five patients enrolled in a late stage trial of tozadenant, a treatment for Parkinson’s, had died.
On this news, Acorda’s share price fell $11.20, or 39.7%, to close at $17.00 on November 15,2017, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Acorda Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.